Therefore, human melanocytes (HM, up to four different donors), immortalized human melanocytes (Hermes), and cutaneous melanoma cell lines, with low, moderate, and high basal BRN3A expression levels representing distinct growth stages, as well as human fibroblasts (HF, two donors, without basal BRN3A expression) (Figure 1B,C), were treated with the DNMT inhibitor 5-Aza-2′deoxycytidine (5-Aza, decitabine) for 48 h. Here, DNMT1 is linked to cutaneous melanoma.